China & KKR & Co.
6 shared events · Importance 3 · Last updated Aug 23, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Business
China: China is the market where mazdutide is being commercialized, representing a high-growth opportunity that underpins the royalty stream and the financing.
KKR & Co.: KKR is the majority owner of Healthcare Royalty, benefiting indirectly from the investment through its subsidiary's expanded portfolio.
Aug 13, 2026 · 6 articles
Business
China: China is a key market for KKR's Asia fund; no direct impact from this event.
KKR & Co.: KKR appointed Roy Gori as senior advisor to bolster its global financial services and insurance strategy, particularly in Asia Pacific.
Jul 21, 2026 · 7 articles
Business
China: Lingyi iTech is a prominent intelligent manufacturing services leader based in China, with its domestic listing on the Shenzhen Stock Exchange.
KKR & Co.: KKR & Co., through Kaide Global Investment, is a cornerstone investor in Lingyi iTech's China — Hong Kong listing, providing significant institutional commitment.
Jun 26, 2026 · 6 articles
Regulatory
China: China is a competitor in AI, and data center growth is part of the global race.
KKR & Co.: KKR is involved in financing data center projects and faces similar risks from community opposition.
Jun 30, 2026 · 151 articles
International
KKR & Co.: KKR & Co. shares gained after the U.S. Department of Labor issued guidelines for adding alternative assets to 401(k) retirement plans, indicating a positive market reaction to regulatory changes.
Mar 30, 2026 · 84 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how China and KKR & Co. interact across events, view sentiment trends, and discover connected entities.
Open Dashboard